Many modern vaccines require adjuvants, and there is a recognized need for newer and more diverse adjuvant choices and even new technologies like VLP.

CBI-3A is a novel vaccine VLP that elicits immune responses from all three elements of the adaptive immune system. It has been studied in multiple animal species with a variety of antigens against multiple pathogens. This versatility makes it a valuable tool for addressing key industry challenges (involving patient populations with impaired immune systems, the limited immunogenicity of recombinant antigens, pathogens that require broad and complex immune responses, and vaccine supply constraints.)